This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy
Recruiting · NCT07144332 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sohag University
View the official record on ClinicalTrials.gov →What this trial is about
Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week. Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively
Who can take part
Inclusion criteria
- We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly
Exclusion criteria
- Patients aged \< 18 years old .
- Patients on recent hemodialysis less than 3 months.
- We excluded patients who were on Uric acid lowering therapy (UALT).
- Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.
Where it is running
1 location listed.
- Sohag university faculty of medicine - Sohag, Egypt